At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of unresectable hepatocellular carcinoma or metastatic liver cancer
- ✓HCC defined by biopsy proof or Barcelona imaging criteria
- ✓Metastatic disease with pathological confirmation and new/enlarging liver lesion
- ✓No untreated or progressive disease outside the liver
- ✕Inability to lie still for imaging studies
- ✕Pregnancy, nursing, or refusal to use birth control in patients capable of reproduction
- ✕Known allergy or contraindication to intravenous iodinated contrast agents
- ✕Allergy or contraindication to MRI contrast (Eovist or Gadolinium)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.
In Brief
A Phase 1 clinical trial evaluating Yttrium-90, Selective Internal Radiation Therapy, and 3 other interventions for Liver Malignancy. Currently recruiting, targeting 70 participants across 1 site.
Detailed Summary
This study will investigate the combination of Ytrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT) followed by Stereotactic Body Radiation Therapy (SBRT). Y-90 SIRT alone or SBRT alone are standard procedures used in the treatment of liver cancer. This study will assess the combination of Y-90 SIRT and SBRT and obtain preliminary information about the side effects and safety of the combination therapy. Additionally, this is the first time that Y-90 PET-CT imaging will be included in planning for SBRT.
Study Details
Timeline
Interventions
Radioactive isotope Y-90 at day 0, administered by selective internal radiation therapy (SIRT)
SIRT at day 0, to administer Yttrium-90 (Y-90) Theraspheres
3-5 fractions over 1-2 weeks, after Y-90 SIRT
Within 3 hours of completing Y-90 SIRT
Glass microspheres containing Y-90, administered at day 0 by SIRT